Clinical Trial Update: Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung [Phase 2]

View source ↗

Summary

Phase 2 study comparing AXL1717 to docetaxel in non-small cell lung cancer has completed, including lung squamous cell carcinoma and lung adenocarcinoma histolo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• AXL1717 (AXL1717)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Axelar AB | Conditions: Non-small-cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED